{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:17:46Z","timestamp":1794313066383,"version":"4.9.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>In the preceding decade, the management of metastatic cutaneous melanoma has been revolutionised with the development of highly effective therapies including immune checkpoint inhibitors (specifically CTLA-4 and PD-1 inhibitors) and targeted therapies (BRAF and MEK inhibitors). The role of chemotherapy in the contemporary management of melanoma is undefined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Extended analyses highlight substantially improved 5-year survival rates of approximately 50% in patients with metastatic melanoma treated with first-line therapies. However, most patients will progress on these first-line treatments. Sequencing of chemotherapy following failure of targeted and immunotherapies is associated with low objective response rates and short progression-free survival, and thus, meaningful benefits to patients are minimal.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Chemotherapy has limited utility in the contemporary management of cutaneous melanoma (with a few exceptions, discussed herein) and should not be the standard treatment sequence following failure of first-line therapies. Instead, enrolment onto clinical trials should be standard-of-care in these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11912-023-01385-6","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T11:03:31Z","timestamp":1680087811000},"page":"609-621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Chemotherapy in Cutaneous Melanoma: Is There Still a Role?"],"prefix":"10.1007","volume":"25","author":[{"given":"James P.","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines P.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone M.","family":"Goldinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"1385_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cncr.22427","volume":"109","author":"HJ Gogas","year":"2007","unstructured":"Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer: Interdiscip Int J Am Cancer Soc. 2007;109:455\u201364.","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"key":"1385_CR2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582\u20138.","journal-title":"Ann Oncol"},{"key":"1385_CR3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535\u201346.","journal-title":"N Engl J Med"},{"key":"1385_CR4","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1200\/JCO.20.00198","volume":"38","author":"R Seth","year":"2020","unstructured":"Seth R, Messersmith H, Kaur V, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol. 2020;38:3947\u201370.","journal-title":"J Clin Oncol"},{"key":"1385_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","volume":"17","author":"DG Coit","year":"2019","unstructured":"Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17:367\u2013402.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1385_CR6","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.annonc.2020.07.004","volume":"31","author":"U Keilholz","year":"2020","unstructured":"Keilholz U, Ascierto PA, Dummer R, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31:1435\u201348.","journal-title":"Ann Oncol"},{"key":"1385_CR7","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","volume":"27","author":"PA Ascierto","year":"2021","unstructured":"Ascierto PA, Dr\u00e9no B, Larkin J, et al. 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation\u2013positive advanced melanoma: extended follow-up of the coBRIM study. Clin Cancer Res. 2021;27:5225\u201335.","journal-title":"Clin Cancer Res"},{"key":"1385_CR8","doi-asserted-by":"crossref","unstructured":"Dummer R, Flaherty KT, Robert C, et al. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600\u2013mutant melanoma. J Clin Oncol 2022:JCO.21.02659.","DOI":"10.1200\/JCO.21.02659"},{"key":"1385_CR9","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626\u201336.","journal-title":"N Engl J Med"},{"key":"1385_CR10","doi-asserted-by":"crossref","unstructured":"Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2000:CD001215.","DOI":"10.1002\/14651858.CD001215"},{"key":"1385_CR11","doi-asserted-by":"crossref","unstructured":"Huncharek M, Caubet JF, McGarry R0. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.\u00a0Melanoma Res. 2001;11:75\u201381.","DOI":"10.1097\/00008390-200102000-00009"},{"key":"1385_CR12","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1634\/theoncologist.12-9-1114","volume":"12","author":"I Quirt","year":"2007","unstructured":"Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist. 2007;12:1114\u201323.","journal-title":"Oncologist"},{"key":"1385_CR13","doi-asserted-by":"publisher","first-page":"158-","DOI":"10.1200\/JCO.2000.18.1.158","volume":"18","author":"MR Middleton","year":"2000","unstructured":"Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-.","journal-title":"J Clin Oncol"},{"key":"1385_CR14","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","volume":"22","author":"MF Avril","year":"2004","unstructured":"Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22:1118\u201325.","journal-title":"J Clin Oncol"},{"key":"1385_CR15","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1002\/1097-0142(19901101)66:9<1873::AID-CNCR2820660904>3.0.CO;2-5","volume":"66","author":"C Jacquillat","year":"1990","unstructured":"Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990;66:1873\u20138.","journal-title":"Cancer"},{"key":"1385_CR16","first-page":"185","volume":"15","author":"PH Wiernik","year":"1993","unstructured":"Wiernik PH, Einzig AI. Taxol in malignant melanoma. J Natl Cancer Inst Monogr. 1993;15:185\u20137.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"1385_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/BF00194546","volume":"9","author":"AI Einzig","year":"1991","unstructured":"Einzig AI, Hochster H, Wiernik PH, et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs. 1991;9:59\u201364.","journal-title":"Invest New Drugs"},{"key":"1385_CR18","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/1097-0142(19900601)65:11<2478::AID-CNCR2820651114>3.0.CO;2-S","volume":"65","author":"SS Legha","year":"1990","unstructured":"Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of taxol in metastatic melanoma. Cancer. 1990;65:2478\u201381.","journal-title":"Cancer"},{"key":"1385_CR19","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1200\/JCO.2008.17.1579","volume":"27","author":"S O'Day","year":"2009","unstructured":"O\u2019Day S, Gonzalez R, Lawson D, et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol. 2009;27:5452\u20138.","journal-title":"J Clin Oncol"},{"key":"1385_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00008390-200402000-00010","volume":"14","author":"AY Bedikian","year":"2004","unstructured":"Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res. 2004;14:63\u20136.","journal-title":"Melanoma Res"},{"key":"1385_CR21","doi-asserted-by":"crossref","unstructured":"Walker L, Schalch H, King DM, Dietrich L, Eastman M, Kwak M, Kim K, Albertini MR. Phase II trial of weekly paclitaxel in patients with advanced melanoma.\u00a0Melanoma Res. 2005;15:453\u20139.","DOI":"10.1097\/00008390-200510000-00015"},{"key":"1385_CR22","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1093\/annonc\/mdv324","volume":"26","author":"EM Hersh","year":"2015","unstructured":"Hersh EM, Del Vecchio M, Brown MP, et al. A randomized, controlled phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-na\u00efve patients with metastatic melanoma. Ann Oncol. 2015;26:2267\u201374.","journal-title":"Ann Oncol"},{"key":"1385_CR23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/annonc\/mdq438","volume":"22","author":"AY Bedikian","year":"2011","unstructured":"Bedikian AY, DeConti RC, Conry R, et al. Phase 3 study of docosahexaenoic acid\u2013paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol. 2011;22:787\u201393.","journal-title":"Ann Oncol"},{"key":"1385_CR24","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1200\/JCO.1995.13.12.2895","volume":"13","author":"AY Bedikian","year":"1995","unstructured":"Bedikian AY, Weiss GR, Legha SS, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol. 1995;13:2895\u20139.","journal-title":"J Clin Oncol"},{"key":"1385_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/BF02993861","volume":"13","author":"AI Einzig","year":"1996","unstructured":"Einzig AI, Schuchter LM, Recio A, Coatsworth S, Rodriquez R, Wiernik PH. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med Oncol. 1996;13:111\u20137.","journal-title":"Med Oncol"},{"key":"1385_CR26","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/0959-8049(94)90456-1","volume":"30","author":"S Aamdal","year":"1994","unstructured":"Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer. 1994;30:1061\u20134.","journal-title":"Eur J Cancer"},{"key":"1385_CR27","first-page":"1993","volume":"7","author":"JM Kirkwood","year":"1993","unstructured":"Kirkwood JM, Agarwala SS. Systemic cytotoxic and biologic therapy of melanoma. PPO Updates. 1993;7:1993\u20132016.","journal-title":"PPO Updates"},{"key":"1385_CR28","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/00008390-200312000-00012","volume":"13","author":"D Glover","year":"2003","unstructured":"Glover D, Ibrahim J, Kirkwood J, et al. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res. 2003;13:619\u201326.","journal-title":"Melanoma Res"},{"key":"1385_CR29","first-page":"171","volume":"71","author":"LM Evans","year":"1987","unstructured":"Evans LM, Casper ES, Rosenbluth R. Phase II trial of carboplatin in advanced malignant melanoma 1, 2. Cancer Treat Rep. 1987;71:171.","journal-title":"Cancer Treat Rep"},{"key":"1385_CR30","doi-asserted-by":"crossref","unstructured":"G\u00fcven K, Kittler H, Wolff K, Pehamberger H. Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients. Melanoma Res. 2001;11:411\u20135.","DOI":"10.1097\/00008390-200108000-00012"},{"key":"1385_CR31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/cncr.21611","volume":"106","author":"RD Rao","year":"2006","unstructured":"Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer: Interdiscip Int J Am Cancer Soc. 2006;106:375\u201382.","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"key":"1385_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/00000421-200206000-00016","volume":"25","author":"FS Hodi","year":"2002","unstructured":"Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002;25:283\u20136.","journal-title":"Am J Clin Oncol"},{"key":"1385_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1200\/JCO.2012.42.1529","volume":"31","author":"KT Flaherty","year":"2013","unstructured":"Flaherty KT, Lee SJ, Zhao F, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013;31:373.","journal-title":"J Clin Oncol"},{"key":"1385_CR34","doi-asserted-by":"publisher","first-page":"2745-","DOI":"10.1200\/JCO.1999.17.9.2745","volume":"17","author":"PB Chapman","year":"1999","unstructured":"Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-.","journal-title":"J Clin Oncol"},{"key":"1385_CR35","doi-asserted-by":"crossref","unstructured":"Hofmann MA, Hauschild A, Mohr P, Garbe C, Weichenthal M, Trefzer U, Drecoll U, Tilgen W, Schadendorf D, Kaatz M, Ulrich J. Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient\u2019s choice: a multicentre Dermatologic Cooperative Oncology Group trial.\u00a0Melanoma Res. 2011;21:516\u201323.","DOI":"10.1097\/CMR.0b013e3283485ff0"},{"key":"1385_CR36","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1002\/1097-0142(19801201)46:11<2346::AID-CNCR2820461104>3.0.CO;2-6","volume":"46","author":"HF Seigler","year":"1980","unstructured":"Seigler HF, Lucas VS Jr, Pickett NJ, Huang AT. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer. 1980;46:2346\u20138.","journal-title":"Cancer"},{"key":"1385_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/00008390-200508000-00010","volume":"15","author":"M-S Vuoristo","year":"2005","unstructured":"Vuoristo M-S, Hahka-Kemppinen M, Parvinen L-M, et al. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-\u03b1 in patients with advanced melanoma. Melanoma Res. 2005;15:291\u20136.","journal-title":"Melanoma Res"},{"key":"1385_CR38","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ejca.2004.04.030","volume":"40","author":"AMM Eggermont","year":"2004","unstructured":"Eggermont AMM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004;40:1825\u201336.","journal-title":"Eur J Cancer"},{"key":"1385_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/978-3-319-22539-5_8","volume-title":"Melanoma","author":"MA Wilson","year":"2016","unstructured":"Wilson MA, Schuchter LM. Chemotherapy for melanoma. In: Kaufman HL, Mehnert JM, editors. Melanoma. Cham: Springer International Publishing; 2016. p. 209\u201329."},{"key":"1385_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1053\/sonc.2002.35238","volume":"29","author":"E Bajetta","year":"2002","unstructured":"Bajetta E, Del Vecchio M, Bernard-Marty C, et al. Metastatic melanoma: chemotherapy. Semin Oncol. 2002;29:427\u201345.","journal-title":"Semin Oncol"},{"key":"1385_CR41","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/JCO.2004.11.044","volume":"22","author":"SS Agarwala","year":"2004","unstructured":"Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004;22:2101\u20137.","journal-title":"J Clin Oncol"},{"key":"1385_CR42","doi-asserted-by":"crossref","unstructured":"Paul MJ, Summers Y, Calvert AH, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 2002;12.","DOI":"10.1097\/00008390-200204000-00011"},{"key":"1385_CR43","unstructured":"Silverman RB, Holladay MW. The organic chemistry of drug design and drug action. Academic press. 2014."},{"key":"1385_CR44","doi-asserted-by":"crossref","unstructured":"Long HJ. Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug.\u00a0Mayo Clin Proc.\u00a01994;69:341\u20135.\u00a0","DOI":"10.1016\/S0025-6196(12)62219-8"},{"key":"1385_CR45","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","volume":"8","author":"RB Weiss","year":"1990","unstructured":"Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263\u20138.","journal-title":"J Clin Oncol"},{"key":"1385_CR46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/OTT.S13836","volume":"4","author":"Y Yamamoto","year":"2011","unstructured":"Yamamoto Y, Kawano I, Iwase H. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther. 2011;4:123.","journal-title":"Onco Targets Ther"},{"key":"1385_CR47","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0168-3659(01)00321-2","volume":"74","author":"MO Bradley","year":"2001","unstructured":"Bradley MO, Swindell CS, Anthony FH, et al. Tumor targeting by conjugation of DHA to paclitaxel. J Control Release. 2001;74:233\u20136.","journal-title":"J Control Release"},{"key":"1385_CR48","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","volume":"5","author":"J Verweij","year":"1994","unstructured":"Verweij J, Clavel M, Chevalier B. Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): not simply two of a kind. Ann Oncol. 1994;5:495\u2013505.","journal-title":"Ann Oncol"},{"key":"1385_CR49","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u201378.","journal-title":"Eur J Pharmacol"},{"key":"1385_CR50","doi-asserted-by":"crossref","unstructured":"Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 1989;64:2024\u20139.","DOI":"10.1002\/1097-0142(19891115)64:10<2024::AID-CNCR2820641010>3.0.CO;2-V"},{"key":"1385_CR51","doi-asserted-by":"crossref","unstructured":"Pasquali S, Hadjinicolaou AV, Sileni VC, Rossi CR, Mocellin S. Systemic treatments for metastatic cutaneous melanoma.\u00a0Cochrane Database Syst Rev. 2018:CD011123.","DOI":"10.1002\/14651858.CD011123.pub2"},{"key":"1385_CR52","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2015.09.013","volume":"53","author":"S Ugurel","year":"2016","unstructured":"Ugurel S, R\u00f6hmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies. Eur J Cancer. 2016;53:125\u201334.","journal-title":"Eur J Cancer"},{"key":"1385_CR53","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.clon.2018.05.005","volume":"30","author":"TP Hanna","year":"2018","unstructured":"\u2022 Hanna TP, Nguyen P, Baetz T, Booth CM, Eisenhauer E. A population-based study of survival impact of new targeted and immune-based therapies for metastatic or unresectable melanoma. Clin Oncol. 2018;30:609\u201317. Significant in highlighting overall trend towards improved survival following the advent of targeted and immunotherapies.","journal-title":"Clin Oncol"},{"key":"1385_CR54","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517\u201326.","journal-title":"N Engl J Med"},{"key":"1385_CR55","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","volume":"33","author":"M Maio","year":"2015","unstructured":"Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33:1191\u20136.","journal-title":"J Clin Oncol"},{"key":"1385_CR56","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","volume":"31","author":"A Ribas","year":"2013","unstructured":"Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31:616.","journal-title":"J Clin Oncol"},{"key":"1385_CR57","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908\u201318.","journal-title":"Lancet Oncol"},{"key":"1385_CR58","doi-asserted-by":"publisher","first-page":"vi379","DOI":"10.1093\/annonc\/mdw379.02","volume":"27","author":"O Hamid","year":"2016","unstructured":"Hamid O, Puzanov I, Dummer R, et al. Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Ann Oncol. 2016;27:vi379.","journal-title":"Ann Oncol"},{"key":"1385_CR59","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2016.07.018","volume":"67","author":"D Schadendorf","year":"2016","unstructured":"Schadendorf D, Dummer R, Hauschild A, et al. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer. 2016;67:46\u201354.","journal-title":"Eur J Cancer"},{"key":"1385_CR60","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375\u201384.","journal-title":"Lancet Oncol"},{"key":"1385_CR61","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","volume":"36","author":"J Larkin","year":"2018","unstructured":"\u2022\u2022 Larkin J, Minor D, D\u2019Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36:383. Significant in showing superiority of nivolumab compared to chemotherapy in long-term follow-up.","journal-title":"J Clin Oncol"},{"key":"1385_CR62","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1200\/JCO.20.00995","volume":"38","author":"C Robert","year":"2020","unstructured":"Robert C, Long GV, Brady B, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol. 2020;38:3937\u201346.","journal-title":"J Clin Oncol"},{"key":"1385_CR63","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/annonc\/mdw265","volume":"27","author":"GV Long","year":"2016","unstructured":"Long GV, Atkinson V, Ascierto PA, et al. Effect of nivolumab on health-related quality of life in patients with treatment-na\u00efve advanced melanoma: results from the phase III CheckMate 066 study. Ann Oncol. 2016;27:1940\u20136.","journal-title":"Ann Oncol"},{"key":"1385_CR64","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-21-1046","volume":"27","author":"AM Di Giacomo","year":"2021","unstructured":"\u2022\u2022 Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, et al. Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases. Clin Cancer Res. 2021;27:4737\u201345. Significant in showing long-term superiority of immunotherapy over chemotherapy (fotemustine) for treating melanoma brain metastases.","journal-title":"Clin Cancer Res"},{"key":"1385_CR65","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323\u201332.","journal-title":"Lancet Oncol"},{"key":"1385_CR66","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","volume":"28","author":"PB Chapman","year":"2017","unstructured":"Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017;28:2581\u20137.","journal-title":"Ann Oncol"},{"key":"1385_CR67","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob J-J, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. The Lancet. 2012;380:358\u201365.","journal-title":"The Lancet"},{"key":"1385_CR68","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2019.10.033","volume":"125","author":"A Hauschild","year":"2020","unstructured":"Hauschild A, Ascierto PA, Schadendorf D, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: analysis from phase 2 and 3 clinical trials. Eur J Cancer. 2020;125:114\u201320.","journal-title":"Eur J Cancer"},{"key":"1385_CR69","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/annonc\/mdu154","volume":"25","author":"JJ Grob","year":"2014","unstructured":"Grob JJ, Amonkar MM, Martin-Algarra S, et al. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Ann Oncol. 2014;25:1428\u201336.","journal-title":"Ann Oncol"},{"key":"1385_CR70","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1158\/1078-0432.CCR-11-1491","volume":"18","author":"JM Kirkwood","year":"2012","unstructured":"Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK1\/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma selumetinib versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012;18:555\u201367.","journal-title":"Clin Cancer Res"},{"key":"1385_CR71","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","volume":"18","author":"R Dummer","year":"2017","unstructured":"Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:435\u201345.","journal-title":"Lancet Oncol"},{"key":"1385_CR72","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.3390\/cancers12071727","volume":"12","author":"C Lebb\u00e9","year":"2020","unstructured":"Lebb\u00e9 C, Dutriaux C, Lesimple T, et al. Pimasertib versus dacarbazine in patients with unresectable NRAS-mutated cutaneous melanoma: phase II, randomized, controlled trial with crossover. Cancers. 2020;12:1727.","journal-title":"Cancers"},{"key":"1385_CR73","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2018.12.015","volume":"109","author":"C Robert","year":"2019","unstructured":"Robert C, Flaherty K, Nathan P, et al. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E\/K\u2013mutant advanced or metastatic melanoma. Eur J Cancer. 2019;109:61\u20139.","journal-title":"Eur J Cancer"},{"key":"1385_CR74","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/annonc\/mdt580","volume":"25","author":"D Schadendorf","year":"2014","unstructured":"Schadendorf D, Amonkar MM, Milhem M, et al. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Ann Oncol. 2014;25:700\u20136.","journal-title":"Ann Oncol"},{"key":"1385_CR75","unstructured":"Group OLoEW. \" The Oxford 2011 Levels of evidence.\" Oxford Centre for Evidence-Based Medicine. http:\/\/www.cebmnet\/indexaspx?o=56532011. Accessed 20 Oct 2022."},{"key":"1385_CR76","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1634\/theoncologist.2009-0325","volume":"15","author":"D Moreno-Ramirez","year":"2010","unstructured":"Moreno-Ramirez D, Cruz-Merino L, Ferrandiz L, Villegas-Portero R, Nieto-Garcia A. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist. 2010;15:416\u201327.","journal-title":"Oncologist"},{"key":"1385_CR77","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/jso.25400","volume":"119","author":"T Read","year":"2019","unstructured":"Read T, Lonne M, Sparks DS, et al. A systematic review and meta-analysis of locoregional treatments for in-transit melanoma. J Surg Oncol. 2019;119:887\u201396.","journal-title":"J Surg Oncol"},{"key":"1385_CR78","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/0284186X.2021.2006776","volume":"61","author":"F Petrelli","year":"2022","unstructured":"Petrelli F, Ghidini A, Simioni A, Campana LG. Impact of electrochemotherapy in metastatic cutaneous melanoma: a contemporary systematic review and meta-analysis. Acta Oncol. 2022;61:533\u201344.","journal-title":"Acta Oncol"},{"key":"1385_CR79","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2022.03.041","volume":"169","author":"C-J Holmberg","year":"2022","unstructured":"Holmberg C-J, Ny L, Hieken TJ, et al. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases \u2013 a multicenter cohort study. Eur J Cancer. 2022;169:210\u201322.","journal-title":"Eur J Cancer"},{"key":"1385_CR80","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","volume":"170","author":"C Garbe","year":"2022","unstructured":"Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. Eur J Cancer. 2022;170:256\u201384.","journal-title":"Eur J Cancer"},{"key":"1385_CR81","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41416-021-01486-8","volume":"125","author":"S Bouchereau","year":"2021","unstructured":"Bouchereau S, Chaplain L, Fort M, et al. Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma. Br J Cancer. 2021;125:948\u201354.","journal-title":"Br J Cancer"},{"key":"1385_CR82","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2021.11.022","volume":"162","author":"SM Goldinger","year":"2022","unstructured":"\u2022\u2022 Goldinger SM, Buder-Bakhaya K, Lo SN, et al. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer. 2022;162:22\u201333. Significant in showing low clinical activity of chemotherapy as a salvage therapy following failure of first-line treatment options.","journal-title":"Eur J Cancer"},{"key":"1385_CR83","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997\u20131003.","journal-title":"N Engl J Med"},{"key":"1385_CR84","doi-asserted-by":"crossref","unstructured":"Ma S, Egyhazi S, Martenhed G, Ringborg U, Hansson J. Analysis of O6-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy.\u00a0Melanoma Res. 2002;12:335\u201342.","DOI":"10.1097\/00008390-200208000-00005"},{"key":"1385_CR85","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.ejca.2010.04.023","volume":"46","author":"C Busch","year":"2010","unstructured":"Busch C, Geisler J, Lillehaug JR, L\u00f8nning PE. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. Eur J Cancer. 2010;46:2127\u201333.","journal-title":"Eur J Cancer"},{"key":"1385_CR86","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/CMR.0000000000000298","volume":"26","author":"O Kube\u010dek","year":"2016","unstructured":"Kube\u010dek O, Kopeck\u00fd J. Microsatellite instability in melanoma: a comprehensive review. Melanoma Res. 2016;26:545\u201350.","journal-title":"Melanoma Res"},{"key":"1385_CR87","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jid.2021.01.024","volume":"141","author":"KB Kim","year":"2021","unstructured":"Kim KB, Soroceanu L, de Semir D, et al. Prevalence of homologous recombination pathway gene mutations in melanoma: rationale for a new targeted therapeutic approach. J Investig Dermatol. 2021;141:2028-36.e2.","journal-title":"J Investig Dermatol"},{"key":"1385_CR88","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-21-1046","volume":"27","author":"AM Di Giacomo","year":"2021","unstructured":"Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, et al. Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases. The NIBIT-M2 phase 3, multicenter, randomized clinical trial. Clin Cancer Res. 2021;27:4737\u201345.","journal-title":"Clin Cancer Res"},{"key":"1385_CR89","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19:672\u201381.","journal-title":"Lancet Oncol"},{"key":"1385_CR90","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722\u201330.","journal-title":"N Engl J Med"},{"key":"1385_CR91","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18:863\u201373.","journal-title":"Lancet Oncol"},{"key":"1385_CR92","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27025","volume":"2","author":"M Roselli","year":"2013","unstructured":"Roselli M, Cereda V, di Bari MG, et al. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology. 2013;2: e27025.","journal-title":"Oncoimmunology"},{"key":"1385_CR93","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108\u201321.","journal-title":"N Engl J Med"},{"key":"1385_CR94","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392.","journal-title":"N Engl J Med"},{"key":"1385_CR95","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/CMR.0000000000000669","volume":"30","author":"J Vera Aguilera","year":"2020","unstructured":"\u2022 Vera Aguilera J, Paludo J, McWilliams RR, et al. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res. 2020;30:364\u201375. Significant in highlighting chemoimmunotherapy combining ICIs and chemotherapy as a potential avenue requiring further research in melanoma.","journal-title":"Melanoma Res"},{"key":"1385_CR96","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.1038\/s41388-021-01879-2","volume":"40","author":"J Alonso-Mara\u00f1\u00f3n","year":"2021","unstructured":"Alonso-Mara\u00f1\u00f3n J, Villanueva A, Piulats JM, et al. Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair. Oncogene. 2021;40:5042\u20138.","journal-title":"Oncogene"},{"key":"1385_CR97","doi-asserted-by":"publisher","first-page":"12607","DOI":"10.18632\/oncotarget.2610","volume":"5","author":"WP Roos","year":"2014","unstructured":"Roos WP, Quiros S, Krumm A, et al. B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells. Oncotarget. 2014;5:12607.","journal-title":"Oncotarget"},{"key":"1385_CR98","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/annonc\/mdy500","volume":"30","author":"V Urbonas","year":"2019","unstructured":"Urbonas V, Schadendorf D, Zimmer L, et al. Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Ann Oncol. 2019;30:317\u201324.","journal-title":"Ann Oncol"},{"key":"1385_CR99","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/annonc\/mdw213","volume":"27","author":"N Cherny","year":"2016","unstructured":"Cherny N, Sullivan R, Torode J, Saar M, Eniu A. ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann Oncol. 2016;27:1423\u201343.","journal-title":"Ann Oncol"},{"key":"1385_CR100","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(21)00463-0","volume":"22","author":"A Fundytus","year":"2021","unstructured":"Fundytus A, Sengar M, Lombe D, et al. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol. 2021;22:1367\u201377.","journal-title":"Lancet Oncol"},{"key":"1385_CR101","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-20-3868","volume":"27","author":"A Magnuson","year":"2021","unstructured":"Magnuson A, Bruinooge SS, Singh H, et al. Modernizing clinical trial eligibility criteria: recommendations of the ASCO-Friends of cancer research performance status work group broadened eligibility: performance status. Clin Cancer Res. 2021;27:2424\u20139.","journal-title":"Clin Cancer Res"},{"key":"1385_CR102","doi-asserted-by":"crossref","unstructured":"Claps G, Faouzi S, Quidville V, Chehade F, Shen S, Vagner S, Robert C. The multiple roles of LDH in cancer. Nat Rev Clin Oncol. 2022;19:749\u201362.","DOI":"10.1038\/s41571-022-00686-2"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01385-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-023-01385-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01385-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T08:22:08Z","timestamp":1683361328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-023-01385-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1385"],"URL":"https:\/\/doi.org\/10.1007\/s11912-023-01385-6","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"4 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ines P. da Silva had travel support by BMS and MSD and speaker fee by Roche, BMS and MSD. Reinhard Dummer has intermittent, project-focused consulting and\/or advisory relationships with Novartis, Merck Sharp & Dohme (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer and touchIME outside the submitted work. James P. Pham, Anthony M. Joshua and Simone M. Goldinger declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}